Protagonist Therapeutics Inc (PTGX)

Gross profit margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Gross profit (ttm)	US$ in thousands	275,294	26,646	-31,948	-31,187	-28,847	-5,035	2,854	12,785	12,902	-8,270	-14,682	-22,622	-20,878	-20,281	-12,530	-11,614	-10,485	-7,321	-7,687	-937
Revenue (ttm)	US$ in thousands	315,090	60,137	123	123	982	26,704	35,221	45,507	46,913	27,380	24,330	27,139	31,091	28,549	25,678	12,604	6,408	4,321	3,955	10,051
Gross profit margin		87.37%	44.31%	-25,973.98%	-25,355.28%	-2,937.58%	-18.85%	8.10%	28.09%	27.50%	-30.20%	-60.35%	-83.36%	-67.15%	-71.04%	-48.80%	-92.15%	-163.62%	-169.43%	-194.36%	-9.32%

March 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $275,294K ÷ $315,090K
= 87.37%

The gross profit margin for Protagonist Therapeutics Inc has shown significant fluctuations over the periods provided. The analysis reveals that the gross profit margin was exceptionally high at 87.37% as of March 31, 2024, indicating that the company had a healthy margin of revenue after accounting for the cost of goods sold.

In contrast, the gross profit margin was negative in several periods, such as -25,973.98% and -25,355.28% in the fourth quarter of 2023 and third quarter of 2023, respectively. These negative margins suggest that the cost of goods sold exceeded the revenue generated during those periods, leading to substantial losses on a gross profit basis.

Overall, the gross profit margin analysis indicates considerable variability in the company's profitability over the examined periods, highlighting the need for further investigation into the factors influencing these fluctuations in order to make informed assessments of Protagonist Therapeutics Inc's financial performance.